Fate Therapeutics CFO sells 6,582 shares for taxes

The sale was automatically executed under an irrevocable election to meet tax withholding obligations, rather than at the CFO’s discretion.

Available on EDGAR 11/04/2026 - 04:01 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

FATE Therapeutics Inc. Chief Financial Officer Kamal Adawi sold 6,582 shares of common stock on November 3, 2026, at a weighted average price of $2.0548 per share. The sale covered tax withholding tied to vesting of 18,750 shares underlying RSUs; Adawi directly held 93,418 shares after the transaction.

Insider Trade Summary

Net Seller: 6,582 shares

Net Sell 1 txn

Insider Adawi Kamal

Role Chief Financial Officer

Sold 6,582 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	6,582	$2.0548	$14K

Holdings After Transaction: Common Stock — 93,418 shares (Direct)

Footnotes (2)

1. F1. Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 18,750 shares of Common Stock underlying RSUs granted to the Reporting Person on October 20, 2025. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
2. F2. Represents the weighted average sale price of the shares sold ranging from $2.020 to $2.084 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

Key Figures

Shares sold: 6,582 shares Weighted average sale price: $2.0548 per share Direct shares held after transaction: 93,418 shares +1 more

4 metrics

Shares sold 6,582 shares November 3, 2026

Weighted average sale price $2.0548 per share Sale prices ranged from $2.020 to $2.084 per share

Direct shares held after transaction 93,418 shares Following the November 3, 2026 sale

Shares underlying RSUs vesting 18,750 shares RSUs granted October 20, 2025

Key Terms

sell-to-cover, RSUs, irrevocable election

3 terms

sell-to-cover technical

"satisfy tax withholding obligations through "sell-to-cover" transactions"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

RSUs financial

"18,750 shares of Common Stock underlying RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

irrevocable election technical

"pursuant to an irrevocable election by the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FATE shares did Kamal Adawi sell, and at what price?

Kamal Adawi sold 6,582 shares on November 3, 2026, at a weighted average price of $2.0548 per share. The reported sale prices ranged from $2.020 to $2.084 per share.

How was Kamal Adawi’s FATE share sale handled?

The shares were automatically sold under an irrevocable election to satisfy tax withholding obligations connected with the vesting of 18,750 shares underlying RSUs. The footnote says the sales were not made at Adawi’s discretion.

How many FATE shares did Kamal Adawi hold after the sale?

Kamal Adawi directly held 93,418 shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adawi Kamal

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2026		S(1)		6,582	D	$2.0548(2)	93,418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 18,750 shares of Common Stock underlying RSUs granted to the Reporting Person on October 20, 2025. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.

2. Represents the weighted average sale price of the shares sold ranging from $2.020 to $2.084 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

	/s/ Cindy Tahl, as Attorney-in-Fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)